A compound called Kisspeptin-10 reduced cellular damage in the testicles of obese rats and improved sperm quality by activating the body’s natural cellular cleanup systems, according to a 2026 animal study published in Reproductive Sciences. Gram Research analysis shows the compound lowered harmful oxidative stress markers and increased protective antioxidants, while improving sperm movement and concentration. However, this research was conducted in rats, not humans, so human clinical trials are needed before doctors could recommend it as a fertility treatment
Obesity damages male reproductive health by creating harmful stress inside cells, particularly in the testicles. Researchers tested a compound called Kisspeptin-10 on obese rats to see if it could reverse this damage. According to Gram Research analysis, the compound reduced cellular damage markers, improved sperm quality, and activated protective cellular cleanup processes. While the results are promising for treating obesity-related infertility in men, the research was conducted in animals and needs human testing before doctors can recommend it as a treatment.
Key Statistics
A 2026 animal study of 40 rats found that Kisspeptin-10 treatment reduced malondialdehyde (a cellular damage marker) and increased glutathione (a protective antioxidant) in obese rats’ testicular tissue, effectively lowering oxidative stress.
In the same 2026 study, Kisspeptin-10 improved sperm motility and concentration in obese rats while reducing the percentage of abnormally shaped sperm, suggesting potential benefits for fertility.
The 2026 research showed that Kisspeptin-10 increased expression of PINK1 and PHB2 proteins, which help remove damaged mitochondria, and increased Beclin-1 expression, supporting the cell’s natural recycling process in obese rats’ testicular tissue.
The Quick Take
- What they studied: Whether a hormone-like compound called Kisspeptin-10 could fix testicular damage and improve sperm quality in obese male rats
- Who participated: Forty male Sprague Dawley rats divided into four groups: normal weight controls, obese rats, normal rats given Kisspeptin-10, and obese rats given Kisspeptin-10. Obesity was induced by feeding rats a high-fat diet for 12 weeks
- Key finding: Kisspeptin-10 reduced harmful oxidative stress in testicular tissue, improved sperm motility and concentration, and activated cellular cleanup mechanisms in obese rats, though mitochondrial function showed only partial improvement
- What it means for you: This research suggests a potential new treatment approach for male infertility caused by obesity, but human clinical trials are needed before this compound could be used in medical practice. Men with obesity-related fertility concerns should consult their doctor about current evidence-based treatments
The Research Details
Researchers used 40 male rats divided into four equal groups to test Kisspeptin-10’s effects on obesity-related testicular damage. First, they created obesity in two groups by feeding them a high-fat diet (60% of calories from fat) for 12 weeks. Then, for the next 4 weeks, they gave Kisspeptin-10 injections to one normal-weight group and one obese group while continuing their respective diets. The other two groups received no treatment. At the end of the study, researchers examined the rats’ testicles, sperm, and cellular markers to measure oxidative stress, sperm quality, and the activity of cellular cleanup and protection systems. They measured harmful molecules like malondialdehyde (a marker of cellular damage) and protective molecules like glutathione (an antioxidant), along with examining sperm movement, concentration, and DNA integrity.
This research approach matters because it allows scientists to understand the specific biological mechanisms by which obesity damages male fertility and how a potential treatment works at the cellular level. Using rats enables researchers to control diet, treatment timing, and genetic factors precisely, which would be impossible in human studies. The detailed examination of cellular cleanup processes (mitophagy and autophagy) helps identify exactly how Kisspeptin-10 might protect reproductive tissue from obesity-related damage
This study has several strengths: it used a controlled experimental design with multiple comparison groups, measured multiple relevant outcomes (oxidative stress, sperm quality, cellular proteins), and examined specific cellular mechanisms. However, the study was conducted in animals, not humans, so results may not directly apply to people. The sample size of 40 rats is reasonable for this type of research. The study was published in a peer-reviewed journal, which means other scientists reviewed it before publication. Readers should note that animal studies often show more dramatic results than human trials
What the Results Show
Obesity significantly damaged the rats’ testicular function and sperm quality. Obese rats showed increased levels of malondialdehyde (a marker of cellular damage) and decreased levels of glutathione (a protective antioxidant), indicating high oxidative stress. Their sperm showed reduced movement and concentration, with more abnormal sperm shapes. When Kisspeptin-10 was given to obese rats, it reduced malondialdehyde levels and increased glutathione levels, effectively lowering oxidative stress. The compound improved sperm motility (movement) and concentration while reducing the percentage of abnormally shaped sperm. Additionally, Kisspeptin-10 treatment activated cellular cleanup proteins called PINK1 and PHB2, which help remove damaged mitochondria (the cell’s energy factories), and increased Beclin-1 expression, which supports cellular autophagy (the cell’s natural recycling process). These changes suggest the compound helps cells protect themselves from obesity-related damage through enhanced quality control mechanisms.
Kisspeptin-10 treatment showed a non-significant trend toward improving mitochondrial membrane potential (the energy status of mitochondria), meaning the effect was present but not strong enough to be statistically reliable. The compound decreased DNA damage in sperm, which is important for fertility and offspring health. Interestingly, Kisspeptin-10 increased prostate weight in treated rats, suggesting it may have broader effects on male reproductive organs. The treatment did not significantly affect certain autophagy markers (LC3-II and Parkin) or apoptosis-related proteins (programmed cell death pathways), indicating that while the compound activates some cellular cleanup mechanisms, its effects on other protective pathways are limited
Previous research has shown that obesity impairs male fertility through multiple mechanisms, including oxidative stress and mitochondrial dysfunction. This study builds on that knowledge by testing a specific compound that previous research suggested might regulate cellular redox balance (the balance between harmful and protective molecules). The findings align with earlier studies showing that mitochondrial quality control is important for male reproductive health. However, this is among the first studies examining Kisspeptin-10 specifically for obesity-related testicular dysfunction, making it a novel contribution to the field. The results are consistent with the compound’s known roles in reproductive hormone signaling
The most significant limitation is that this research was conducted in rats, not humans, so results may not directly translate to people. The study did not measure all possible cellular pathways, so other protective mechanisms may be at work. The improvement in mitochondrial function was only partial and not statistically significant, suggesting Kisspeptin-10 may not fully restore mitochondrial health. The study lasted only 4 weeks of treatment, so long-term effects are unknown. The research did not examine whether the benefits persist after treatment stops or whether higher or lower doses might be more effective. Additionally, the study did not test Kisspeptin-10 in rats with other obesity-related conditions, so its broader health effects remain unclear
The Bottom Line
Based on this animal research, Kisspeptin-10 shows promise as a potential treatment for obesity-related male infertility, but human clinical trials are necessary before it can be recommended for medical use. Men experiencing infertility related to obesity should consult reproductive endocrinologists about proven treatments, which currently include weight loss, lifestyle modifications, and in some cases, assisted reproductive technologies. This research suggests a future treatment avenue but should not change current medical practice. Confidence in these findings is moderate because they come from animal studies; human evidence would provide much stronger support
This research is most relevant to men with obesity-related infertility, reproductive endocrinologists and urologists treating male infertility, obesity researchers, and pharmaceutical companies developing new fertility treatments. Men without fertility concerns or those whose infertility has other causes may not benefit from this specific treatment. Women and non-reproductive health professionals should note this research as background information on male fertility but need not apply it directly. Researchers studying mitochondrial dysfunction and cellular quality control mechanisms will find this work relevant to their fields
In the rat study, Kisspeptin-10 showed effects within 4 weeks of treatment. If this compound advances to human trials, it would likely take 5 to 10 years before becoming available as a medical treatment, following standard drug development and regulatory approval processes. Even if approved, realistic expectations would be gradual improvement in sperm quality over weeks to months of treatment, similar to other fertility interventions. Men seeking fertility improvements should not expect immediate results from any treatment and should plan for ongoing monitoring and adjustment
Frequently Asked Questions
Can Kisspeptin-10 treat male infertility caused by obesity?
Kisspeptin-10 shows promise in animal studies for improving sperm quality and reducing testicular damage from obesity, but human clinical trials have not yet been conducted. Current proven treatments for obesity-related infertility include weight loss, lifestyle changes, and assisted reproductive technologies. Consult a fertility specialist about available options
How does obesity damage male fertility and sperm?
Obesity increases oxidative stress (harmful cellular damage) and mitochondrial dysfunction (energy factory problems) in testicular tissue. This reduces sperm movement, concentration, and DNA integrity. The 2026 study found that obese rats had significantly elevated cellular damage markers and reduced protective antioxidants in their testicles
What is mitophagy and why does it matter for fertility?
Mitophagy is the cell’s natural process of removing damaged mitochondria (energy-producing structures). Healthy mitochondria are essential for sperm function and energy production. The study found that Kisspeptin-10 activated mitophagy-related proteins, suggesting it helps cells maintain healthy mitochondria and protect reproductive tissue
When will Kisspeptin-10 be available as a fertility treatment?
Kisspeptin-10 is not yet available as a medical treatment. Animal studies like this one typically precede human clinical trials by several years. If development continues, human trials would need to demonstrate safety and effectiveness before regulatory approval, a process that typically takes 5 to 10 years
What can men with obesity do now to improve fertility?
Evidence-based approaches include losing weight through reduced calorie intake and increased exercise, improving diet quality, reducing alcohol consumption, and avoiding smoking. Even modest weight loss of 5 to 10 percent can improve sperm parameters. Consult a reproductive endocrinologist for personalized guidance and fertility testing
Want to Apply This Research?
- Track sperm quality parameters if undergoing fertility testing: record sperm concentration (million per milliliter), motility percentage (moving sperm), and morphology (normal shape percentage) at baseline and every 4 to 8 weeks during any treatment. Also track body weight and waist circumference weekly, as weight loss often improves fertility outcomes
- Use the app to log daily weight, diet composition (especially fat intake), and exercise minutes. Set a goal to reduce caloric intake by 500 to 750 calories daily and increase physical activity to 150 minutes weekly, as weight loss is the most evidence-based intervention for obesity-related infertility. Create reminders for medical appointments and fertility testing
- Establish a baseline assessment including body weight, BMI, and fertility testing results. Monitor weight loss progress monthly with a target of 1 to 2 pounds per week. Schedule repeat fertility testing every 3 to 6 months to track improvements in sperm parameters. Log any changes in energy levels, sexual function, or other health markers. Share tracked data with your healthcare provider to adjust treatment plans based on progress
This article summarizes animal research and is for educational purposes only. Kisspeptin-10 is not approved by the FDA for treating human infertility and is not currently available as a medical treatment. The findings from rat studies do not guarantee similar results in humans. Men experiencing infertility should consult a board-certified reproductive endocrinologist or urologist for diagnosis and evidence-based treatment options. Do not attempt to obtain or use Kisspeptin-10 outside of approved clinical trials. This information should not replace professional medical advice
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.